Marianna Paulis graduated in Biological Sciences in 2000 at
the University of Pavia, where she also obtained a PhD in Genetic and
Biomolecular Sciences in 2004. During her PhD, she attended the
Advanced School for Integrated Formation (SAFI) established by the University
School for Advanced Studies (IUSS) of Pavia for 3 years and achieved the certificate of
advanced post-graduate education in 2004. Since 2006, she has been working at
the National Research Council (CNR) of Milan with a Post-Doctoral position and
in 2007, in her laboratory moved to the Humanitas Research Hospital. In 2015, she
received a tenured position as a Researcher at the Institute of Genetic and
Biomedical Research (IRGB) of the CNR based in Milan. She has long-lasting
research experience and expertise in the field of classical and molecular
cytogenetics of mammalian cells and years of experience in mouse and human
pluripotent stem cells (both ESCs and iPSCs). Her main interest is in the
investigation of gene therapy approaches for genome disorders due to
chromosomal abnormalities.
Marianna Paulis graduated in Biological Sciences in 2000 at
the University of Pavia, where she also obtained a PhD in Genetic and
Biomolecular Sciences in 2004. During her PhD, she attended the
Advanced School for Integrated Formation (SAFI) established by the University
School for Advanced Studies (IUSS) of Pavia for 3 years and achieved the certificate of
advanced post-graduate education in 2004. Since 2006, she has been working at
the National Research Council (CNR) of Milan with a Post-Doctoral position and
in 2007, in her laboratory moved to the Humanitas Research Hospital. In 2015, she
received a tenured position as a Researcher at the Institute of Genetic and
Biomedical Research (IRGB) of the CNR based in Milan. She has long-lasting
research experience and expertise in the field of classical and molecular
cytogenetics of mammalian cells and years of experience in mouse and human
pluripotent stem cells (both ESCs and iPSCs). Her main interest is in the
investigation of gene therapy approaches for genome disorders due to
chromosomal abnormalities.